Skip to main content
Top

06-07-2024 | Gestational Diabetes | Review article

A closer look at Galectin-3: its association with gestational diabetes mellitus revealed by systematic review and meta-analysis

Authors: Seyed Sobhan Bahreiny, Akram Ahangarpour, Mojtaba Aghaei, Reza Mohammadpour Fard, Mohammad Ali Jalali Far, Tannaz Sakhavarz

Published in: Journal of Diabetes & Metabolic Disorders

Login to get access

Abstract

Purpose

Gestational diabetes mellitus (GDM) represents a significant metabolic disorder that affects pregnant women worldwide and has negative consequences for both the mother and her offspring. This research aims to investigate the relation between circulating levels of Galectin-3 and the incidence of GDM, and to evaluate its potential as a biomarker for monitoring and early detection of the disease.

Methods

A thorough search of the literature has been performed using databases such as Scopus, Web of science, Embase, Cochrane Library and PubMed. The standardized mean difference (SMD) and corresponding confidence intervals (CIs) were used to compute the effect size from individual records and pooled using the Random-effect model.

Results

Our meta-analysis synthesized data from 9 studies, encompassing 1,286 participants (533 GDM patients and 753 healthy pregnant controls). The findings demonstrated a considerable increase in Galectin-3 levels among individuals diagnosed with GDM as compared to the healthy control (SMD = 0.929; CI: 0.179–1.679; p = 0.015), with observed heterogeneity (I2 = 87%; p < 0.001). Subgroup analyses revealed the influence of factors such as age, BMI, study design, and sample type on Galectin-3 levels. A meta-regression analysis further identified trends indicating that levels of Galectin-3 are linked to gestational age, specific geographical areas, and sample size.

Conclusion

Increased levels of Galectin-3 exhibit a significant association with GDM, indicating its prospective utility as a biomarker for early detection and risk assessment. Further research is warranted to elucidate its regulation and clinical implications in GDM management.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am, 2007. 34(2): p. 173– 99, vii. Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am, 2007. 34(2): p. 173– 99, vii.
2.
go back to reference Catalano PM, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780–6.PubMedPubMedCentralCrossRef Catalano PM, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780–6.PubMedPubMedCentralCrossRef
3.
go back to reference Hedderson MM, Ferrara A, Sacks DA. Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Obstet Gynecol. 2003;102(4):850–6.PubMed Hedderson MM, Ferrara A, Sacks DA. Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Obstet Gynecol. 2003;102(4):850–6.PubMed
5.
go back to reference Group HSCR. Hyperglycaemia and adverse pregnancy outcome (HAPO) study: associations with maternal body mass index. BJOG: Int J Obstet Gynecol. 2010;117(5):575–84.CrossRef Group HSCR. Hyperglycaemia and adverse pregnancy outcome (HAPO) study: associations with maternal body mass index. BJOG: Int J Obstet Gynecol. 2010;117(5):575–84.CrossRef
6.
go back to reference Geurtsen ML, et al. High maternal early-pregnancy blood glucose levels are associated with altered fetal growth and increased risk of adverse birth outcomes. Diabetologia. 2019;62(10):1880–90.PubMedPubMedCentralCrossRef Geurtsen ML, et al. High maternal early-pregnancy blood glucose levels are associated with altered fetal growth and increased risk of adverse birth outcomes. Diabetologia. 2019;62(10):1880–90.PubMedPubMedCentralCrossRef
7.
go back to reference Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis of gestational diabetes Mellitus: a prospective cohort study of Nulliparous Women. Diabetes Care. 2016;39(6):982–7.PubMedCrossRef Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis of gestational diabetes Mellitus: a prospective cohort study of Nulliparous Women. Diabetes Care. 2016;39(6):982–7.PubMedCrossRef
8.
go back to reference Bahreiny SS, Ahangarpour A, Aghaei M. Circulating levels of advanced glycation end products in females with polycystic ovary syndrome: a meta-analysis. Reproductive Dev Med. 2024;8(2):93–100.CrossRef Bahreiny SS, Ahangarpour A, Aghaei M. Circulating levels of advanced glycation end products in females with polycystic ovary syndrome: a meta-analysis. Reproductive Dev Med. 2024;8(2):93–100.CrossRef
9.
go back to reference Sletner L, et al. Fetal growth trajectories in pregnancies of European and south Asian mothers with and without gestational diabetes, a population-based cohort study. PLoS ONE. 2017;12(3):e0172946.PubMedPubMedCentralCrossRef Sletner L, et al. Fetal growth trajectories in pregnancies of European and south Asian mothers with and without gestational diabetes, a population-based cohort study. PLoS ONE. 2017;12(3):e0172946.PubMedPubMedCentralCrossRef
10.
go back to reference Hoverfelt A, et al. DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes. Diabetologia. 2010;53(9):1903–7.PubMedCrossRef Hoverfelt A, et al. DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes. Diabetologia. 2010;53(9):1903–7.PubMedCrossRef
11.
go back to reference Hutter S, et al. Placental expression patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in cases of Intrauterine Growth restriction (IUGR). Int J Mol Sci. 2016;17(4):523.PubMedPubMedCentralCrossRef Hutter S, et al. Placental expression patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in cases of Intrauterine Growth restriction (IUGR). Int J Mol Sci. 2016;17(4):523.PubMedPubMedCentralCrossRef
12.
go back to reference Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.PubMedCrossRef Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.PubMedCrossRef
13.
14.
go back to reference Yilmaz H, et al. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Invest. 2015;38(5):527–33.PubMedCrossRef Yilmaz H, et al. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Invest. 2015;38(5):527–33.PubMedCrossRef
15.
go back to reference Talmor-Barkan Y, et al. Elevated galectin-3 in women with gestational diabetes mellitus, a new surrogate for cardiovascular disease in women. PLoS ONE. 2020;15(6):e0234732.PubMedPubMedCentralCrossRef Talmor-Barkan Y, et al. Elevated galectin-3 in women with gestational diabetes mellitus, a new surrogate for cardiovascular disease in women. PLoS ONE. 2020;15(6):e0234732.PubMedPubMedCentralCrossRef
16.
go back to reference Bahreiny SS, et al. Circulating Galectin-3 levels in women with polycystic ovary syndrome: a meta-analysis. Taiwan J Obstet Gynecol. 2024;63(1):37–45.PubMedCrossRef Bahreiny SS, et al. Circulating Galectin-3 levels in women with polycystic ovary syndrome: a meta-analysis. Taiwan J Obstet Gynecol. 2024;63(1):37–45.PubMedCrossRef
17.
go back to reference Bichara M, et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology. 2006;16(1):36–45.PubMedCrossRef Bichara M, et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology. 2006;16(1):36–45.PubMedCrossRef
18.
go back to reference Freitag N, et al. The chimera-type galectin-3 is a positive modulator of trophoblast functions with dysregulated expression in gestational diabetes mellitus. Am J Reprod Immunol. 2020;84(6):e13311.PubMedCrossRef Freitag N, et al. The chimera-type galectin-3 is a positive modulator of trophoblast functions with dysregulated expression in gestational diabetes mellitus. Am J Reprod Immunol. 2020;84(6):e13311.PubMedCrossRef
19.
go back to reference Deng Y, et al. Elevated galectin-3 levels detected in women with hyperglycemia during early and mid-pregnancy antagonizes high glucose - induced trophoblast cells apoptosis via galectin-3/foxc1 pathway. Mol Med. 2023;29(1):115.PubMedPubMedCentralCrossRef Deng Y, et al. Elevated galectin-3 levels detected in women with hyperglycemia during early and mid-pregnancy antagonizes high glucose - induced trophoblast cells apoptosis via galectin-3/foxc1 pathway. Mol Med. 2023;29(1):115.PubMedPubMedCentralCrossRef
20.
go back to reference Pejnovic NN, et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62(6):1932–44.PubMedPubMedCentralCrossRef Pejnovic NN, et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62(6):1932–44.PubMedPubMedCentralCrossRef
21.
22.
go back to reference Mensah-Brown EP, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol. 2009;130(1):83–8.PubMedCrossRef Mensah-Brown EP, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol. 2009;130(1):83–8.PubMedCrossRef
23.
go back to reference Sun Z, et al. Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt. Am J Physiol Heart Circ Physiol. 2021;320(1):H364–80.PubMedCrossRef Sun Z, et al. Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt. Am J Physiol Heart Circ Physiol. 2021;320(1):H364–80.PubMedCrossRef
25.
go back to reference Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement1):S14–31.CrossRef Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement1):S14–31.CrossRef
26.
go back to reference Zhang M, et al. Current guidelines on the management of gestational diabetes mellitus: a content analysis and appraisal. BMC Pregnancy Childbirth. 2019;19:1–15. Zhang M, et al. Current guidelines on the management of gestational diabetes mellitus: a content analysis and appraisal. BMC Pregnancy Childbirth. 2019;19:1–15.
27.
go back to reference Todi S, Sagili H, Kamalanathan SK. Comparison of criteria of International Association of Diabetes and pregnancy study groups (IADPSG) with National Institute for Health and Care Excellence (NICE) for diagnosis of gestational diabetes mellitus. Arch Gynecol Obstet. 2020;302:47–52.PubMedCrossRef Todi S, Sagili H, Kamalanathan SK. Comparison of criteria of International Association of Diabetes and pregnancy study groups (IADPSG) with National Institute for Health and Care Excellence (NICE) for diagnosis of gestational diabetes mellitus. Arch Gynecol Obstet. 2020;302:47–52.PubMedCrossRef
28.
go back to reference Bahreiny SS, et al. Association between ambient particulate matter and semen quality parameters: a systematic review and meta-analysis. Middle East Fertility Soc J. 2024;29(1):2.CrossRef Bahreiny SS, et al. Association between ambient particulate matter and semen quality parameters: a systematic review and meta-analysis. Middle East Fertility Soc J. 2024;29(1):2.CrossRef
29.
go back to reference Bahreiny SS, et al. Autoimmune thyroid disorders and polycystic ovary syndrome: tracing links through systematic review and meta-analysis. J Reprod Immunol. 2024;163:104215.PubMedCrossRef Bahreiny SS, et al. Autoimmune thyroid disorders and polycystic ovary syndrome: tracing links through systematic review and meta-analysis. J Reprod Immunol. 2024;163:104215.PubMedCrossRef
30.
go back to reference Peterson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Volume 2. Ottawa: Ottawa Hospital Research Institute; 2011. pp. 1–12. 1. Peterson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Volume 2. Ottawa: Ottawa Hospital Research Institute; 2011. pp. 1–12. 1.
31.
go back to reference Xuan Nguyen K et al. Low-grade inflammation in gestational diabetes mellitus and its correlation with maternal insulin resistance and fetal growth indices. Int J Gen Med, 2023: p. 1429–36. Xuan Nguyen K et al. Low-grade inflammation in gestational diabetes mellitus and its correlation with maternal insulin resistance and fetal growth indices. Int J Gen Med, 2023: p. 1429–36.
32.
go back to reference Mahdizade AH, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: a systematic review and meta-analysis. International Journal of Diabetes in Developing Countries; 2023. Mahdizade AH, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: a systematic review and meta-analysis. International Journal of Diabetes in Developing Countries; 2023.
33.
go back to reference Shirakawa K, et al. IL (interleukin)-10–STAT3–galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation. 2018;138(18):2021–35.PubMedCrossRef Shirakawa K, et al. IL (interleukin)-10–STAT3–galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation. 2018;138(18):2021–35.PubMedCrossRef
34.
35.
go back to reference Krautbauer S, et al. Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice. Cytokine. 2014;69(2):263–71.PubMedCrossRef Krautbauer S, et al. Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice. Cytokine. 2014;69(2):263–71.PubMedCrossRef
36.
go back to reference Weigert J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metabolism. 2010;95(3):1404–11.CrossRef Weigert J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metabolism. 2010;95(3):1404–11.CrossRef
37.
go back to reference Hedderson MM, et al. Low prepregnancy adiponectin concentrations are associated with a marked increase in risk for development of gestational diabetes mellitus. Diabetes Care. 2013;36(12):3930–7.PubMedPubMedCentralCrossRef Hedderson MM, et al. Low prepregnancy adiponectin concentrations are associated with a marked increase in risk for development of gestational diabetes mellitus. Diabetes Care. 2013;36(12):3930–7.PubMedPubMedCentralCrossRef
38.
go back to reference Weber M, et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett. 2009;583(22):3718–24.PubMedCrossRef Weber M, et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett. 2009;583(22):3718–24.PubMedCrossRef
39.
go back to reference Yang H, et al. The antiapoptotic effect of galectin-3 in human endometrial cells under the regulation of estrogen and progesterone. Biol Reprod. 2012;87(2):1–7.CrossRef Yang H, et al. The antiapoptotic effect of galectin-3 in human endometrial cells under the regulation of estrogen and progesterone. Biol Reprod. 2012;87(2):1–7.CrossRef
40.
go back to reference Wang L, et al. Combined effects of progesterone and SOCS3 DNA methylation on T2DM: a case–control study. Clin Epigenetics. 2021;13:1–13.CrossRef Wang L, et al. Combined effects of progesterone and SOCS3 DNA methylation on T2DM: a case–control study. Clin Epigenetics. 2021;13:1–13.CrossRef
42.
go back to reference Bahreiny SS, et al. Association of Free Radical product and polycystic ovary syndrome: a systematic review and Meta-analysis. Reproductive Sci. 2024;31(6):1486–95.CrossRef Bahreiny SS, et al. Association of Free Radical product and polycystic ovary syndrome: a systematic review and Meta-analysis. Reproductive Sci. 2024;31(6):1486–95.CrossRef
43.
go back to reference Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015;14:1–13.CrossRef Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015;14:1–13.CrossRef
44.
go back to reference Li Y-S, et al. Roles of galectin-3 in metabolic disorders and tumor cell metabolism. Int J Biol Macromol. 2020;142:463–73.PubMedCrossRef Li Y-S, et al. Roles of galectin-3 in metabolic disorders and tumor cell metabolism. Int J Biol Macromol. 2020;142:463–73.PubMedCrossRef
45.
go back to reference Liu Y, et al. Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis. Clin Immunol. 2022;236:108939.PubMedCrossRef Liu Y, et al. Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis. Clin Immunol. 2022;236:108939.PubMedCrossRef
46.
go back to reference Papaspyridonos M, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28(3):433–40.PubMedCrossRef Papaspyridonos M, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28(3):433–40.PubMedCrossRef
47.
go back to reference Ou HC, et al. Galectin-3 aggravates ox‐LDL‐induced endothelial dysfunction through LOX‐1 mediated signaling pathway. Environ Toxicol. 2019;34(7):825–35.PubMedCrossRef Ou HC, et al. Galectin-3 aggravates ox‐LDL‐induced endothelial dysfunction through LOX‐1 mediated signaling pathway. Environ Toxicol. 2019;34(7):825–35.PubMedCrossRef
48.
go back to reference Padgett CA, et al. Galectin-3 mediates vascular dysfunction in obesity by regulating NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2023;43(10):e381–95.PubMedCrossRef Padgett CA, et al. Galectin-3 mediates vascular dysfunction in obesity by regulating NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2023;43(10):e381–95.PubMedCrossRef
49.
go back to reference Ottanelli S, et al. Hypertension and preeclampsia in pregnancy complicated by diabetes, in gestational diabetes. Karger; 2020. pp. 171–82. Ottanelli S, et al. Hypertension and preeclampsia in pregnancy complicated by diabetes, in gestational diabetes. Karger; 2020. pp. 171–82.
50.
go back to reference Wang Y, Wang Y. The role of Slit-2 in Gestational Diabetes Mellitus and its effect on pregnancy outcome. Front Endocrinol. 2022;13:889505.CrossRef Wang Y, Wang Y. The role of Slit-2 in Gestational Diabetes Mellitus and its effect on pregnancy outcome. Front Endocrinol. 2022;13:889505.CrossRef
51.
go back to reference Gencheva D, et al. Serum Galectin-3 in women with gestational hypertension and Preeclampsia and its Association with Preterm Birth. Acta Medica Iranica; 2021. Gencheva D, et al. Serum Galectin-3 in women with gestational hypertension and Preeclampsia and its Association with Preterm Birth. Acta Medica Iranica; 2021.
52.
go back to reference Martin KE, et al. The influence of maternal BMI and gestational diabetes on pregnancy outcome. Diabetes Res Clin Pract. 2015;108(3):508–13.PubMedCrossRef Martin KE, et al. The influence of maternal BMI and gestational diabetes on pregnancy outcome. Diabetes Res Clin Pract. 2015;108(3):508–13.PubMedCrossRef
53.
go back to reference Zhang H, et al. Potential biomarkers identified in plasma of patients with gestational diabetes mellitus. Metabolomics. 2021;17(11):99.PubMedCrossRef Zhang H, et al. Potential biomarkers identified in plasma of patients with gestational diabetes mellitus. Metabolomics. 2021;17(11):99.PubMedCrossRef
54.
go back to reference Enquobahrie DA, et al. Maternal early pregnancy serum metabolites and risk of gestational diabetes mellitus. J Clin Endocrinol Metabolism. 2015;100(11):4348–56.CrossRef Enquobahrie DA, et al. Maternal early pregnancy serum metabolites and risk of gestational diabetes mellitus. J Clin Endocrinol Metabolism. 2015;100(11):4348–56.CrossRef
55.
go back to reference Paulo MS, et al. Gestational diabetes mellitus in Europe: a systematic review and meta-analysis of prevalence studies. Front Endocrinol. 2021;12:691033.CrossRef Paulo MS, et al. Gestational diabetes mellitus in Europe: a systematic review and meta-analysis of prevalence studies. Front Endocrinol. 2021;12:691033.CrossRef
56.
go back to reference Chen F, et al. Predictive plasma biomarker for gestational diabetes: a case-control study in China. J Proteom. 2023;271:104769.CrossRef Chen F, et al. Predictive plasma biomarker for gestational diabetes: a case-control study in China. J Proteom. 2023;271:104769.CrossRef
57.
go back to reference Larijani B. A review on the prevalence of gestational diabetes mellitus (GDM) in different regions of Iran. J Diabetes Metab Disord. 2009;8:7. Larijani B. A review on the prevalence of gestational diabetes mellitus (GDM) in different regions of Iran. J Diabetes Metab Disord. 2009;8:7.
58.
go back to reference Al-Rifai RH, et al. Prevalence of gestational diabetes mellitus in the Middle East and North Africa, 2000–2019: a systematic review, Meta-analysis, and Meta-Regression. Front Endocrinol. 2021;12:668447.CrossRef Al-Rifai RH, et al. Prevalence of gestational diabetes mellitus in the Middle East and North Africa, 2000–2019: a systematic review, Meta-analysis, and Meta-Regression. Front Endocrinol. 2021;12:668447.CrossRef
59.
go back to reference Naeh A, et al. Early identification of the maternal, placental and fetal dialog in gestational diabetes and its Prevention. Reproductive Med. 2021;3(1):1–14.CrossRef Naeh A, et al. Early identification of the maternal, placental and fetal dialog in gestational diabetes and its Prevention. Reproductive Med. 2021;3(1):1–14.CrossRef
60.
go back to reference Baldane S, et al. Assessment of serum galectin-3 levels in patients with gestational diabetes mellitus. J Diabetol. 2023;14(1):28–33.CrossRef Baldane S, et al. Assessment of serum galectin-3 levels in patients with gestational diabetes mellitus. J Diabetol. 2023;14(1):28–33.CrossRef
61.
go back to reference Tang T, Chen L. Correlation between serum ApoC III and Galectin-3 levels and maternal and neonatal adverse outcomes in gestational diabetes Mellitus Patients Emergency Medicine International, 2022. 2022. Tang T, Chen L. Correlation between serum ApoC III and Galectin-3 levels and maternal and neonatal adverse outcomes in gestational diabetes Mellitus Patients Emergency Medicine International, 2022. 2022.
62.
go back to reference Heusler I, et al. Enhanced expression of Galectin-3 in gestational diabetes. Nutr Metabolism Cardiovasc Dis. 2021;31(6):1791–7.CrossRef Heusler I, et al. Enhanced expression of Galectin-3 in gestational diabetes. Nutr Metabolism Cardiovasc Dis. 2021;31(6):1791–7.CrossRef
63.
go back to reference Zhang Z, et al. Association of circulating galectin-3 with gestational diabetes mellitus, progesterone, and insulin resistance. J Diabetes. 2021;13(1):54–62.PubMedCrossRef Zhang Z, et al. Association of circulating galectin-3 with gestational diabetes mellitus, progesterone, and insulin resistance. J Diabetes. 2021;13(1):54–62.PubMedCrossRef
Metadata
Title
A closer look at Galectin-3: its association with gestational diabetes mellitus revealed by systematic review and meta-analysis
Authors
Seyed Sobhan Bahreiny
Akram Ahangarpour
Mojtaba Aghaei
Reza Mohammadpour Fard
Mohammad Ali Jalali Far
Tannaz Sakhavarz
Publication date
06-07-2024
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-024-01461-z
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare